Nature Cancer

Article	Citations
Untangling the threads of immunotherapy research	535
Outcompeting neighbors for intestinal cancer initiation	342
Gut decisions in CAR T cell therapy	339
A low-coverage liquid biopsy for lung cancer	301
Alzheimer’s drug turns macrophages against cancer	296
PARP11 interfer(on)es with CAR T cell efficacy	274
Enhancing childhood cancer targetability	259
Shooting for multiplexed pathology with Orion	254
An oncolytic circular RNA therapy	252
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	233
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	230
A macrophage-activated abscopal effect	228
Breaking frontiers with multidisciplinary cancer research	197
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	185
MALAT1 protects dormant tumor cells from immune elimination	185
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	178
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	175
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	167
Considering molecular alterations as pan-cancer tissue-agnostic targets	165
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	159
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	158
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	148
The cGAS–STING pathway and cancer	147
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	140
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment	140

Expanding the options for KRAS inhibition	134
The importance of being generous	129
Reflecting on the golden age of cancer research	125
DePICting T cell–APC crosstalk in cancer	123
Beating cancer one carbon at a time	121
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	120
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	113
Bone marrow progenitor-like cells against leukemia cure	113
Shaping the microenvironment in peritoneal metastases	106
Palmitate oxidation drives a pro-metastatic post-translational modification	106
Determinants of resistance and response to melanoma therapy	103
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	101
Impact of context-dependent autophagy states on tumor progression	100
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	100
Engineering-enhanced CAR T cells for improved cancer therapy	100
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy	100
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	99
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	98
The labors of referees	98
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	97
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	94
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	92
LAG-3 and PD-1 blockade raises the bar for melanoma	92
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	89
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	88
Thriving in diverse ecosystems	86
Inflammation meets translation in AML	84
A quick guide for clinical oncology	84
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	84
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	83
Sarcoma ecotypes determine immunotherapy benefit	82
A comeback for checkpoint inhibition in multiple myeloma	81
Antibody avidity meets multiple myeloma	81
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	81
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	79
Cycling back to folate metabolism in cancer	77
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	77
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas	77
Multimodal data integration improves immunotherapy response prediction	75
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	75
Radioligand cancer therapy comes to the fore	74
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	73
How AI agents will change cancer research and oncology	73
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	73
Bispecific antibodies seek out colon cancer stem cells	72
Immunotargeting of a recurrent AML-specific neoantigen	72
A Wnt twist in FTO’s role in cancer progression	71
Dual inhibition of EGFR and PI3K with a single drug	71
Author Correction: Engineering-enhanced CAR T cells for improved cancer therapy	71
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	70

Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages	70
Radiation sparks a dark side in neutrophils	70
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping	69
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	68
Building a translational cancer dependency map for The Cancer Genome Atlas	67
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma	67
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors	67
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	66
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma	66
GEMys homing in on metastasis	65
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment	65
Targeting BRCA-mutated tumors in mitosis	63
Selective targeting of malignant T cells	62
Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissues	62
AKTing on XPO1 inhibition in AML	62
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export	62
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models	61
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition	60
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer	59
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	59
Bispecific chimeric T cell receptors tackle tumor heterogeneity	58
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer	58
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	58
The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets	58
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors	57
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	57
Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming	56
Advances in antibody-based therapy in oncology	56
Anything to declare?	56
Epigenetic plasticity in PDAC	56
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	55
From the editor’s desk	55
There are gremlins in prostate cancer	55
Neoadjuvant immunotherapy marks a new era in oncology	55
Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia	54
Metabolic symbiosis in pancreatic cancer	54
Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	53
Ricolinostat is not a highly selective HDAC6 inhibitor	53
Myeloma evades T cell-engaging therapies	53
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer	52
An antisense RNA promotes breast cancer metastasis via upregulation of NQO1	50
Targeting ADAR1 with a small molecule for the treatment of prostate cancer	49
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes	49
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy	49
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy	48
p53 at the crossroads of tumor immunity	48
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy	48
Estrogen receptor-positive breast cancer subtypes show differential macrophage functions	47
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment	47
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia	47
Epigenetic Achilles’ heel of AML	47
Clinical and translational attributes of immune-related adverse events	46
Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration	46
Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer	46
In vivo macrophage engineering for renal cancer therapy	46
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	45
Circumventing the roadblocks to targeting EGFR-driven cancers	44
A new sophistication for breast cancer PDXs	44
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	44
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome	43
2-HG modulates glioma macrophages via Trp metabolism	42
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	42
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors	42
Masking T cell engagers mitigates on-target off-tumor activity	42
Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	42
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	41
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	41
CD8+ T cell killing of MHC class I–deficient tumors	41
Breaking the performance ceiling for neoantigen immunogenicity prediction	41
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	40
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples	40
CAR T cell therapy: looking back and looking forward	40
Understanding the biology of lung cancer brain metastases	39
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	39
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	38
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	38
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	38
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	38
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy	38
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	37

Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	37
Global loss of promoter–enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis	36
The meaning of impact	36
Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics	36
Communicating with respect	36
Harnessing the microbiome to restore immunotherapy response	36
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)	35
CD4+ CAR T cells — more than helpers	35
Leveraging the potential for deintensification in cancer care	35
Leveraging translational insights toward precision medicine approaches for brain metastases	34
Insight from the ESMO Targeted Anticancer Therapies Congress 2025	34
Near-infrared optogenetic engineering of bacteria for cancer therapy	34
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens	33
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance	33
Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer	33
Acute lymphoblastic leukemia displays a distinct highly methylated genome	33
Targeting HIF-1 to treat AML	32
‘IL-2Rα-biased’ IL-2 for cancer immunotherapy	32
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy	32
The aging lung reawakens dormant tumor cells	32
Commensal metabolite boosts chemotherapy	32
Disparities, aging and childhood cancer	32
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients	31
The landscape of T cell antigens for cancer immunotherapy	31
Immunoradiotherapy goes club(bing)	31
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5	31
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells	30
Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer	30
Fibrotic tumors tune metabolism for immune evasion	30
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer	30
Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis	30
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism	29
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells	29